Bulk Inquiry
WAY 362450
- FXR 450 - XL 335
Axon 1749
CAS:
629664-81-9
Purity:
99%
- Soluble in DMSO
- MF: C25H24F2N2O3
- MW: 438.47
Description
A highly potent, selective, and orally bioavailable farnesoid X receptor (FXR) agonist (EC50: 4 nM, eff=149%); potently induces luciferase reporter expression with an EC50 value of 16 nMpotently induces luciferase reporter expression with an EC50 value of 16 nM
More Information
| Parent CAS No. | 629664-81-9 |
|---|---|
| Chemical Name | Isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate |
| SMILES | C12C=CC=CC=1NC1C(C(OC(C)C)=O)=CN(C(=O)C3C=C(F)C(F)=CC=3)CC(C)(C)C=12 |
| MFCD | MFCD13181507 |
| InChi | InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3 |
| InChiKey | INASOKQDNHHMRE-UHFFFAOYSA-N |
| CID | 10026128 |
| Short Description | FXR agonist |
References
- B Flutt et al. Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR). J. Med. Chem. 2009, 52(4), 904–907.
- MJ Evans et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296(3), G543-G552.
- HB Hartman et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice. J. Lipid Res. 2009, 50(6), 1090-1100.
- S Zhang et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009, 51(2), 380-388.
Other Categories
Get a Quote for
Loading...
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.